In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.
J. W. Wotring, S. M. McCarty, K. Shafiq, C. J. Zhang, T. Nguyen, S. R. Meyer, R. Fursmidt, C. Mirabelli, M. C. Clasby, C. E. Wobus, M. J. O'Meara, J. Z. Sexton
This study evaluates niclosamide's limitations as a COVID-19 treatment and identifies analogs with improved potency and reduced toxicity.
bioRxiv · Jun 24, 2022Microbiology